NCT06533644ClinicalTrials.gov

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

מגייסמקבל משתתפים כעת, לפי רשומת המרשם.

יצירת קשר עם המחקר

בקצרה

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.

שלב 2דרושים 91 משתתפים23 אתריםמדינה אחת

קטגוריות

אונקולוגיה68%נפרולוגיה ואורולוגיה32%

רשום במרשם אחד

ClinicalTrials.govNCT06533644פתיחת רשומה זו ב־ClinicalTrials.govסונכרן לפני חודשיים

מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.

מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.

מתעניינים במחקר הזה?

התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2024-08-01; recorded start 2025-05-29
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Present: Participants are randomly assignedAllocation is recorded as randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Not stated: Open label (no blinding)Masking is recorded as none (open label)
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Syncromune, Inc.)
Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: industry.
Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourMODERATE

A moderately rigorous design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation20/20
Participants are randomly allocated between arms
Blinding0/20
Open-label
Control arm0/15
No comparator arm stated in the record
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 23 sites
Data monitoring committee7/7
A data monitoring committee is in place
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleSMALL

A small study: 91 participants (target), run at 23 sites.

How this score is built

Enrolment18/40
91 participants (target)
Site count16/25
23 sites
Country count0/15
Single country
Planned duration8/10
Planned over about 35 months
Sponsor scale0/10
Syncromune, Inc. has led 1 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

תקציר

מצבים רפואיים

Metastatic Castration-resistant Prostate Cancer

זכאות

זכאות
מין	זכר
גילאים	18 Years – ללא מקסימום
מתנדבים בריאים	לא

זכאות כפי שנכתבה במרשם

Inclusion Criteria: * Male \>=18 years old. * Able to provide written informed consent and comply with the study procedures. * Participants with advanced and/or metastatic histologically or cytologically confirmed adenocarcinoma of the prostate without small cell histology or neuroendocrine transformation. * Serum testosterone levels less than or equal to (\<=) 0.5 nanograms per millilitre (ng/mL) (\<=1.73 nanomoles per litre \[nmol/L\]) at screening if on an androgen receptor prostate inhibitor in combination with Androgen Deprivation Therapy (ADT). * Progression (as defined below) after the receipt of at least one or more approved second-generation androgen-receptor-pathway inhibitors with or without a prior course of taxane therapy, as long as the subject has not received more than three lines of therapy in the CRPC setting. If a subject is known positive for any of the specific gene mutations of BRCA1/2, PALB2, or HRD and chose not to receive an approved PARP-inhibitor they are eligible for the study. Documented progressive disease at screening as assessed by the Investigator with at least one of the following criteria: * Serum/plasma PSA progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week apart. 1.0 ng/mL is the minimal starting value if confirmed rise is only indication of progression. * Radiographic disease progression in soft tissue based on response evaluation criteria in solid tumors (RECIST) v1.1 criteria with or without PSA progression as per prostate cancer working group 3 (PCWG3). * Radiographic disease progression in bone defined as the appearance of 2 or more new bone lesions on a bone scan as per PCWG3 with or without PSA progression. * Able to undergo general anesthesia, MAC anesthesia, or conscious sedation. * Eastern Cooperative Oncology Group (ECOG) performance status of less than (\<) 2. * Life expectancy \>=6 months * Last dose of previous anticancer therapy (excluding hormonal therapy) must by 28 days prior to first study treatment. For subjects who previously received lutetium Lu 177 vipivotide tetraxetan (Pluvicto®), the last dose must have been administered \> 90 days prior to first study treatment. Subjects may remain on ADT and/or androgen receptor pathway inhibitor at time of study entry, per Investigator discretion. * Resolution of all acute toxic effects (excluding alopecia) of any prior anticancer therapy. * For males with female partners of childbearing potential, even if surgically sterilized (that is \[i.e.\], status post vasectomy), who agree to practice: 1. effective barrier contraception during the treatment period and through 120-150 days after last dose, OR 2. true abstinence, when this is in line with the preferred and usual lifestyle of the participants. Periodic abstinence (for example \[e.g.\], calendar, ovulation, symptothermal, post ovulation methods), withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together. * Must have at least one measurable lesion per RECIST v1.1 at time of screening. * Must have at least one lesion suitable for SYNC-T Therapy identified by radiographic imaging as defined below: * Soft tissue lesion (e.g., prostate, lung) must be at least 1 cm in at least two dimensions. * Lymph node lesion of at least 1.5 cm (short axis) or 1.0 cm if positive per PET scan. * Exophytic component of a bone lesion that is measurable per RECIST v1.1. Soft tissue and lymph nodes must be demonstrable on CT/MRI and accessible either transperineally or percutaneously to permit tumor biopsy, cryolysis, and immunotherapy infusion. The eligible tumor lesion for intratumoral infusion cannot be a tumor that is adjacent to vital structures such as major nerves or blood vessels or at risk of airway compromise in the event of post-infusion tumor swelling/inflammation. * Participants receiving bone resorptive therapy must be on stable doses for at least 42 days prior to the oncolysis. * In the opinion of the Investigator, there is no other meaningful life prolonging therapy option available, or the participant refuses other therapy, outside of anti-hormonal therapy. * Adequate bone marrow, renal, and hepatic function. * Participants agrees to provide tumor tissue and undergo an on-treatment tumor biopsy. Exclusion Criteria: * Has a known other primary malignancy other than prostate cancer that is progressing or has required active treatment in the last 3 years, excluding basal and squamous cell carcinoma, papillary thyroid cancer, and ductal carcinoma in situ of the breast. * Has an obstructed urinary system before or after stenting. * Has undergone major surgery, including local prostate intervention (excluding prostate biopsy), within 28 days prior to the first dose of study treatment and has not recovered adequately from the toxicities and/or complications. * Has used any anticoagulants or other blood thinners pre-study treatments within the protocol-defined timelines. * Has an active infection (including tuberculosis) requiring systemic therapy. * Has a history of non-infectious pneumonitis that requires steroids. * Has received a live vaccine within 30 days prior to the planned first study treatment. * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 28 days prior to the first study treatment. * Significant cardiac or other medical illness such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia (e.g., New York Heart Association Class 4), or history of previous heart failure. * Fridericia corrected QT interval (QTcF) greater than (\>) 470 millisecond (msec) (men) on a 12-lead electrocardiogram (ECG) during the screening period. * Malignant pleural effusions or ascites that require immediate intervention. * Brain metastases (includes history of). * Immunocompromised status due to: * Active autoimmune diseases such as Addison's disease, Hashimoto's thyroiditis, systemic lupus erythematosus, Sjogren syndrome, scleroderma, myasthenia gravis, Goodpasture syndrome or active Grave's disease. Participants with a history of autoimmunity that has not required systemic immunosuppressive therapy or does not threaten vital organ function including CNS, heart, lungs, kidneys, skin, and GI tract will be allowed. * Other immunodeficiency diseases that in the opinion of the Investigator, with consultation with Medical Monitor, could compromise the participant or limit treatment efficacy. * Uncontrolled or unmanaged diabetes, hypersensitivity, or other illness or disease that in the opinion of the Investigator, with consultation with Medical Monitor (MM), makes the subject a poor candidate. * History of bone marrow/stem cell transplant. * Participants having human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS) are not eligible for enrollment. * Active coronavirus disease-2019 (COVID-19) infection or tests positive for COVID-19 a day before or the day of planned study treatment. * Participants who have active viral (any etiology) hepatitis are excluded. * Participants with serologic evidence of chronic hepatitis B virus (HBV) infection (defined by a positive hepatitis B surface antigen \[HBsAg\] test and a positive hepatitis B core antibody (anti-HBc) test) who have a viral load below the limit quantification (HBV deoxyribonucleic acid \[DNA\] titer \<1000 copies per milliliters \[cps/mL\] or 200 international units per milliliter \[IU/mL\]) and are not currently on viral suppressive therapy may be eligible and should be discussed with the Sponsor's Medical Monitor. * Participants with a history of hepatitis C virus (HCV) infection should have completed curative antiviral treatment and have a viral load below the limit of quantification are eligible for study entry. Known or suspected hepatitis C infection which has not been treated and cured are not eligible. Known or suspected hepatitis C currently on treatment with an undetectable viral load are eligible. Patients with a history of hepatitis C virus (HCV) infection should have completed curative antiviral treatment and have a viral load below the limit of quantification are eligible for study entry. * Participants with complications or contraindications related to the liver, including intrahepatic biliary ductal dilation, uncorrectable bleeding diathesis, and decompensated liver failure. * Breast cancer gene (BRCA) mutation testing will be required for participants not previously treated with a PARP inhibitor, unless BRCA status is established prior to screening. If PARP-positive and participants agree to PARP therapy, they will be ineligible. * Any condition(s) that, in the opinion of the Investigator, would increase the risk for toxicities from study treatment, or interfere with participants compliance or conduct of this study. * Known visceral metastases, except for lung metastases. * Known substance abuse or medical, psychological, or social conditions that may interfere with patient's participation. * Participants who have received both chemotherapy and lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in the CRPC setting.

זכאות במשפטים פשוטים

הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.

תכנון המחקר

תכנון המחקר
סוג המחקר	התערבותי
שלב	שלב 2
הקצאה	אקראי
מודל ההתערבות	SEQUENTIAL
מטרה ראשית	TREATMENT
הסתרה	NONE (0)
גיוס	דרושים 91 משתתפים

נותן חסות ושותפים

Syncromune, Inc. נותן חסות

זרועות והתערבויות

Part 1 - Dose Escalation, Cohort 1: Partial Oncolysis + SV-102EXPERIMENTAL
Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, Dose Level 1.
Part 1 - Dose Escalation, Cohort 2: Partial Oncolysis + SV-102EXPERIMENTAL
Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, Dose Level 2.
Part 1 - Dose Escalation, Cohort 3: Partial Oncolysis + SV-102EXPERIMENTAL
Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, Dose Level 3.
Part 2 - Dose Optimization, Arm 1: Partial Oncolysis + SV-102EXPERIMENTAL
Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, dose level selected from Part 1.
Part 2 - Dose Optimization, Arm 2: Partial Oncolysis + SV-102EXPERIMENTAL
Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, dose level selected from Part 1.

התערבויות

פרוצדורה Partial Oncolysis
Partial tumor oncolysis will be completed by cryolysis.
תרופה SV-102
Intratumoral infusion of SV-102

מדדי תוצאה

מדד תוצאה ראשוני
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Immune-related Adverse Reactions (imARs)
מסגרת זמן Up to 2 years
מדד תוצאה ראשוני
Maximum Tolerated Dose
The MTD will be defined as the highest dose level below the dose level at which 2 or more participant experience a dose limiting toxicity (DLT).
מסגרת זמן Up to 48 weeks
מדד תוצאה ראשוני
Optimal Biologic Dose (OBD)
OBD will be determined based on DLT and dose escalation part data.
מסגרת זמן Up to 48 weeks
מדד תוצאה ראשוני
Recommended Phase 2 Dose (RP2D)
The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for the expansion phase, based on data collected during the dose escalation portion of the study.
מסגרת זמן Up to 48 weeks
מדד תוצאה ראשוני
Objective Response Rate (ORR)
The ORR is defined as the percentage of participants who achieved best overall response (BOR) of complete response (CR) or partial response (PR).
מסגרת זמן Up to 2 years
מדד תוצאה משני
Duration of Response
The period from the onset of a response (e.g., tumor shrinkage or stabilization) until disease progression or death, whichever occurs first.
מסגרת זמן Up to 2 years
מדד תוצאה משני
Radiographic Progression-Free Survival (rPFS) per RECIST v1.1 and Prostate Cancer Working Group 3 (PCWG3)
rPFS is defined as the time from the start of study drug until first documented radiologic disease progression at the first site of disease or death from any cause, whichever comes first.
מסגרת זמן Up to 2 years
מדד תוצאה משני
Progression-Free Survival (PFS)
The time interval between the start of treatment and the occurrence of disease progression or death from any cause.
מסגרת זמן Up to 2 years
מדד תוצאה משני
Overall survival (OS)
OS is defined as the time from the first dose of study drug to death due to any cause.
מסגרת זמן Up to 2 years
מדד תוצאה משני
Trough Concentration (Ctrough) of SV-102
מסגרת זמן Pre-infusion at Day 1 of Cycle 1 up to Cycle 12 (each cycle length = 28 days)
מדד תוצאה משני
Area Under the Concentration Time Curve From Time 0 to the Time t (AUC0-t) of SV-102
מסגרת זמן Cycle 1: Pre-infusion up to 672 hours post-infusion; Cycle 3: Pre-infusion up to 72 hours post-infusion (each cycle length = 28 days)
מדד תוצאה משני
Area Under the Concentration Time Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of SV-102
מסגרת זמן Cycle 1: Pre-infusion up to 672 hours post-infusion; Cycle 3: Pre-infusion up to 72 hours post-infusion (each cycle length = 28 days)
מדד תוצאה משני
Maximum Observed Plasma Concentration (Cmax) of SV-102
מסגרת זמן Cycle 1: Pre-infusion up to 672 hours post-infusion; Cycle 3: Pre-infusion up to 72 hours post-infusion (each cycle length = 28 days)
מדד תוצאה משני
Last Observed (Quantifiable) Concentration (Clast) of SV-102
מסגרת זמן Cycle 1: Pre-infusion up to 672 hours post-infusion; Cycle 3: Pre-infusion up to 72 hours post-infusion (each cycle length = 28 days)
מדד תוצאה משני
Time to Reach the Maximum Plasma Concentration (Tmax) of SV-102
מסגרת זמן Cycle 1: Pre-infusion up to 672 hours post-infusion; Cycle 3: Pre-infusion up to 72 hours post-infusion (each cycle length = 28 days)
מדד תוצאה משני
Time of Last Measurable Concentration (Tlast) of SV-102
מסגרת זמן Cycle 1: Pre-infusion up to 672 hours post-infusion; Cycle 3: Pre-infusion up to 72 hours post-infusion (each cycle length = 28 days)
מדד תוצאה משני
Apparent Terminal Elimination Half-life (T1/2) of SV-102
מסגרת זמן Cycle 1: Pre-infusion up to 672 hours post-infusion; Cycle 3: Pre-infusion up to 72 hours post-infusion (each cycle length = 28 days)
מדד תוצאה משני
Apparent Total Body Clearance (CL/F) of SV-102
מסגרת זמן Cycle 1: Pre-infusion up to 672 hours post-infusion; Cycle 3: Pre-infusion up to 72 hours post-infusion (each cycle length = 28 days)
מדד תוצאה משני
Volume of Distribution (Vd) of SV-102
מסגרת זמן Cycle 1: Pre-infusion up to 672 hours post-infusion; Cycle 3: Pre-infusion up to 72 hours post-infusion (each cycle length = 28 days)
מדד תוצאה משני
Number of Participants With Any Device Constituent Failures/Malfunctions
מסגרת זמן Up to 2 years
מדד תוצאה משני
Number of Participants With Anti-drug Antibodies (ADA)
מסגרת זמן Up to 2 years

תאריכים

תאריכים
תאריך התחלה	29 במאי 2025 (בפועל)
סיום ראשוני	14 באפריל 2028 (משוער)
סיום	14 באפריל 2028 (משוער)
פורסם לראשונה	1 באוגוסט 2024 (בפועל)
עודכן לאחרונה	23 ביוני 2026
התוצאות פורסמו	לא צוין ברשומת המרשם
המצב אומת לאחרונה	יוני 2026

בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.

מיקומים

14 אתרים מגייסים

United States

United States
מתקן	עיר	מדינה או אזור	מצב
University of Chicago	Chicago	Illinois	טרם מגייס
Ohio State University	Columbus	Ohio	מגייס
Houston Metro Urology	Houston	Texas	טרם מגייס
Mayo Clinic	Jacksonville	Florida	טרם מגייס
Northwell Health	Lake Success	New York	מגייס
Duly Health	Lisle	Illinois	מגייס
Arkansas Urology	Little Rock	Arkansas	טרם מגייס
University of Miami	Miami	Florida	מגייס
Medical College of Wisconsin	Milwaukee	Wisconsin	טרם מגייס
Summit Urology	Murray	Utah	טרם מגייס
NYU Langone	New York	New York	מגייס
Weill Cornell	New York	New York	מגייס
University of Nebraska Medical Center	Omaha	Nebraska	מגייס
Thomas Jefferson University	Philadelphia	Pennsylvania	טרם מגייס
Mayo Clinic	Phoenix	Arizona	טרם מגייס
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	מגייס
University of California-Davis	Sacramento	California	מגייס
Willis Knighton	Shreveport	Louisiana	טרם מגייס
Mercy Hospital	St Louis	Missouri	מגייס
Moffitt Cancer Center	Tampa	Florida	מגייס
Michigan Institute of Urology	Troy	Michigan	מגייס
University of Arizona Cancer Center	Tucson	Arizona	מגייס
Wichita Urology	Wichita	Kansas	מגייס

מסמכי המחקר

לא צורפו מסמכים ברשומת מרשם זו.

שינויים לאורך זמן

לא נרשמו שינויים מאז שקלטנו רשומה זו לראשונה.

שינוי נרשם בכל פעם שנותן החסות מעדכן את רשומת המרשם. מצב, תאריכים, גיוס ואתרים מופיעים כאן ככל שהם משתנים.

מרשם: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT06533644